INVO BioScience, Inc. - Common Stock (INVO)

Recently, numerous companies have garnered attention in the media for various reasons, potentially drawing interest from investors. This article provides a thorough analysis of five companies that should not be overlooked and are worth monitoring.

INVO Bioscience, Inc. (NASDAQ: INVO) is one today’s most active stocks by volume. So far today, approximately 117.5M shares of INVO Bioscience, Inc. have been exchanged, as compared to an average 30-day volume of 25,386 shares.

AVENTURA, Fla. and SARASOTA, Fla., Jan. 23, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences Inc. ("NAYA"), a company which has recently signed a definitive merger agreement with INVO Bioscience to establish an expanded, publicly-traded life science company dedicated to increasing patient access to breakthrough treatments in oncology, regenerative medicine, and fertility, today announced that it has entered into a binding letter of intent to acquire Florida Biotechnologies, Inc. a gene therapy company focusing on the treatment of mitochondrial diseases.

SARASOTA, Fla. and AVENTURA, Fla., Jan. 17, 2024 (GLOBE NEWSWIRE) -- INVO Bioscience, a healthcare services company focused on expanding access to advanced fertility treatment worldwide, which has recently signed a definitive merger agreement with NAYA Biosciences (“NAYA”) to establish an expanded, publicly traded life science company, today announced that it has filed S-4 registration and preliminary joint proxy statements in connection with the upcoming merger.

INVO Bioscience, Inc. (NASDAQ: INVO) is one of today’s top gainers. The company’s shares have moved 1.15% on the day to $1.31.

Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued a comprehensive analysis on INVO Bioscience, Inc. a healthcare services company focused on expanding access to advanced fertility treatment worldwide.

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of INVO Bioscience, Inc. (the “Company”) (NasdaqCM: INVO) with NAYA Biosciences Inc. Under the terms of the proposed transaction, (subject to the Interim PIPE, post-transaction and prior to the private offering), INVO shareholders will own approximately 12% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate and fair to the Company’s shareholders.

INVO Bioscience, Inc. (NASDAQ: INVO) is one today’s most active stocks by volume. So far today, approximately 61.15M shares of INVO Bioscience, Inc. have been exchanged, as compared to an average 30-day volume of 60,767 shares.

BALA CYNWYD, Pa., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

EQNX::TICKER_START (NASDAQ:TCBP),(NYSE:CVM),(NASDAQ:INVO),(NASDAQ:SNY),(NYSE:PFE) EQNX::TICKER_END

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of INVO Bioscience, Inc. (NASDAQ: INVO) and NAYA Biosciences Inc. is fair to INVO shareholders.

SAN FRANCISCO, CA / ACCESSWIRE / February 9, 2022 / Today, the global fertility market is a multi-billion industry, yet remains severely underserved, with estimates suggesting more than 90% of couples in need of infertility treatment going without care. INVO Bioscience (NASDAQ:INVO), a commercial-stage fertility company focused on expanding access to advanced treatment worldwide with its INVOcell® medical device and the IVC procedure it